Personalis, Inc. (NASDAQ:PSNL) Shares Sold by XTX Topco Ltd

XTX Topco Ltd cut its position in shares of Personalis, Inc. (NASDAQ:PSNL) by 77.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,912 shares of the company’s stock after selling 100,646 shares during the quarter. XTX Topco Ltd owned about 0.06% of Personalis worth $34,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ARK Investment Management LLC increased its stake in Personalis by 4.9% during the second quarter. ARK Investment Management LLC now owns 6,361,886 shares of the company’s stock worth $7,443,000 after acquiring an additional 296,413 shares during the last quarter. Acadian Asset Management LLC increased its stake in Personalis by 6.7% during the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock worth $1,237,000 after acquiring an additional 66,128 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Personalis by 144.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company’s stock worth $1,224,000 after acquiring an additional 485,822 shares during the last quarter. State of Michigan Retirement System increased its stake in Personalis by 11.3% during the first quarter. State of Michigan Retirement System now owns 493,798 shares of the company’s stock worth $736,000 after acquiring an additional 50,000 shares during the last quarter. Finally, GSA Capital Partners LLP increased its stake in Personalis by 6.2% during the first quarter. GSA Capital Partners LLP now owns 420,141 shares of the company’s stock worth $626,000 after acquiring an additional 24,498 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Stock Performance

PSNL stock opened at $4.82 on Thursday. Personalis, Inc. has a 1 year low of $0.89 and a 1 year high of $7.20. The firm has a market cap of $255.85 million, a P/E ratio of -2.54 and a beta of 1.91. The stock has a 50-day simple moving average of $4.90 and a 200-day simple moving average of $2.68.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.10. The firm had revenue of $22.58 million during the quarter, compared to the consensus estimate of $19.81 million. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. During the same quarter in the prior year, the business posted ($0.50) earnings per share. On average, equities research analysts predict that Personalis, Inc. will post -1.15 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. HC Wainwright increased their target price on Personalis from $7.50 to $9.00 and gave the company a “buy” rating in a research note on Monday, August 19th. BTIG Research increased their target price on Personalis from $5.50 to $7.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Needham & Company LLC increased their target price on Personalis from $5.50 to $7.25 and gave the company a “buy” rating in a research note on Friday, August 16th.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.